Evidence map›Paper›PMID 41566544›Full record

ReviewChinese medicine2026

Fatty acid metabolism: opportunities and challenges of traditional Chinese medicine in the treatment of renal fibrosis.

Ran-Ran Gao, Cong Han, Wei Li

Abstract readReview
In one paragraph

Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ran-Ran GaoThe First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Cong HanNephropathy Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. hancong_kidney@hotmail.com.
Wei LiNephropathy Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. lweidw@163.com.

Funding

National Natural Science Foundation of China 82204886National Natural Science Foundation of China 82474252Natural Science Foundation of Shandong Province ZR2022QH133
6 · The paper itself

Abstract

Renal fibrosis (RF), as a critical pathological process in the progression of chronic kidney disease (CKD) to end-stage renal disease, currently lacks clear and effective reversal measures. Disordered fatty acid metabolism is highly involved in this process. Studies have revealed that molecular crosstalk under fatty acid metabolism dysregulation-such as lipotoxicity, mitochondrial damage, immune inflammation, epigenetics, metabolic reprogramming, and the gut-kidney axis-drives damage to renal tubules, glomeruli, and the interstitium. Therapeutic strategies targeting fatty acid metabolism to ameliorate RF have gradually become a research hotspot, though most current drugs are still in the clinical exploration stage, and the predictive and therapeutic value of many biomarkers remains to be validated. Traditional Chinese Medicine (TCM), with its personalized and modernized approach combining oral administration and external treatments such as acupuncture, enema, and nanodelivery, is increasingly demonstrating advantages in targeting fatty acid metabolism to improve RF. This review outlines the mechanisms and core targets of TCM in regulating fatty acid metabolism to ameliorate RF. The multi-target advantage based on complex components presents an opportunity for TCM to improve RF, though current research still faces challenges such as mechanistic complexity, standardization of TCM, and clinical translation. Future efforts should integrate multi-omics technologies, novel drug delivery systems, and disease-syndrome combination models to advance the development of new integrated Chinese and Western medicine drugs for RF.

Indexed as

Fatty acid metabolismLipotoxicityMitochondrial dysfunctionMultiple targetsRenal fibrosisTraditional Chinese medicine

Identifiers

PMID41566544
PMCPMC12822352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.